Albany, NY -- (SBWIRE) -- 04/10/2019 -- Bronchopulmonary dysplasia - Epidemiology and Market Forecast-2028

There are 10,000–15,000 new cases of Bronchopulmonary Dysplasia annually in the United States.

1. 10–20% of all infants born between 23 and 31 weeks of postmenstrual age, developed Bronchopulmonary Dysplasia in Europe.
2. Bronchopulmonary Dysplasia incidence reported being up to 77% in infants born less than 32 weeks of gestation with a birth weight below 1 kg.
3. The overall incidence from moderate to severe Bronchopulmonary Dysplasia is greater than 40% in preterm infants.

DelveInsight launched a new report on Bronchopulmonary Dysplasia - Market Insights, Epidemiology and Market Forecast-2028

Request for sample pages

Key benefits

1. Bronchopulmonary Dysplasia market report covers a descriptive overview and comprehensive insight of the Bronchopulmonary Dysplasia epidemiology and Bronchopulmonary Dysplasia Market in the 7 MM (the United States, Eu5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Bronchopulmonary Dysplasia market report provides insights on the current and emerging therapies.
3. Bronchopulmonary Dysplasia market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Bronchopulmonary Dysplasia market report provides an edge that will help in developing business strategies, by understanding trends shaping and driving the Bronchopulmonary Dysplasia Market.

"Bronchopulmonary Dysplasia incidence in surviving infants is less than or equal to 28 weeks gestational age and has been relatively stable at approximately 40% over the last few decades."

Bronchopulmonary Dysplasia Treatment is conceptualized into three stages including; prevention, treatment of evolving Bronchopulmonary Dysplasia and treatment of established Bronchopulmonary Dysplasia.

Management of established Bronchopulmonary Dysplasia includes the use of Inhaled nitric oxide (iNO) (which not only improves oxygenation but has a positive effect on lung development), Diuretics (improves pulmonary mechanics and reduces supplemental oxygen requirements), and other therapies (Inhaled or nebulized bronchodilators such as b-agonists and anticholinergic may transiently reduce airway resistance and hence improve pulmonary compliance in infants with the disease).

Many pharmaceuticals companies are developing therapies for the Bronchopulmonary Dysplasia treatment to tackle unmet needs. Over recent years, important steps have been taken towards an understanding of Bronchopulmonary Dysplasia, and several potential therapeutic targets have also been identified. Further progress in the research and development is likely to translate into improvement in the treatment options for patients with Bronchopulmonary Dysplasia and is anticipated to boost the revenue growth of Bronchopulmonary Dysplasia therapeutics market.

Companies Covered
1. Windtree Therapeutics
2. Shire
3. Medipost Co.
4. Mallinckrodt
And many others

Drugs covered
1. AEROSURF
2. SHP607
3. Pneumostem
4. Inhaled Nitric oxide
And many others

Key Topics Covered
1. Report Introduction
2. Bronchopulmonary Dysplasia Market Overview at a Glance
3. Bronchopulmonary Dysplasia Disease Background and Overview
4. Bronchopulmonary Dysplasia Epidemiology and Patient Population
4.1. United States
4.2. EU-5
4.2.1. Germany
4.2.2 France
4.2.3. Italy
4.2.4. Spain
4.2.5. United Kingdom
4.3. Spain
5. Bronchopulmonary Dysplasia Treatments & Medical Practices
6. Emerging Therapies
7. Key Cross Competition
7.1. AEROSURF: Windtree Therapeutics
7.2. Inhaled Nitric Oxide: Mallinckrodt
8. Bronchopulmonary Dysplasia Market Size
9. 7MM Invasive Pneumococcal Disease: Country-Wise Market Analysis
10. United States Market Size
11. Germany Market Size
12. France Market Size
13. United Kingdom Market Size
14. Spain Market Size
15. Italy Market Size
16. Japan Market Size
17. Report Methodology
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight